Gambaran Umum
Atai Life Sciences N.V., headquartered in the Netherlands, operates primarily within the biotechnology sector, specializing in the development of treatments for mental health disorders. The company employs a unique approach by focusing on psychedelic and non-psychedelic compounds to innovate solutions for conditions that are typically resistant to conventional therapies. A key pillar of Atai Life Sciences' work revolves around leveraging advanced scientific research to demystify and effectively target the underlying biological mechanisms of mental illnesses. Central to their mission, Atai invests in a diverse portfolio of therapeutic projects that explore novel drug development pathways, including the exploration of psilocybin and other compounds, to address significant unmet medical needs in the psychiatric space, aiming at revolutionizing the mental health treatment landscape.
Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai revenue untuk Atai Life Sciences N.V. per 2025 Jun 30 adalah 2.31 MM.
- Nilai operating income untuk Atai Life Sciences N.V. per 2025 Jun 30 adalah -95.60 MM.
- Nilai net income untuk Atai Life Sciences N.V. per 2025 Jun 30 adalah -119.40 MM.
| Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
| 2025-06-30 | 2.31 | -95.60 | -119.40 |
| 2025-03-31 | 1.86 | -96.86 | -148.99 |
| 2024-12-31 | 0.31 | -99.77 | -149.27 |
| 2024-09-30 | 0.33 | -105.98 | -128.60 |
| 2024-06-30 | 0.38 | -107.01 | -58.07 |
| 2024-03-31 | 0.28 | -114.44 | -33.80 |
| 2023-12-31 | 0.31 | -122.27 | -40.22 |
| 2023-09-30 | 0.33 | -126.28 | -66.94 |
| 2023-06-30 | 0.27 | -141.06 | -145.08 |
| 2023-03-31 | 0.27 | -141.00 | -148.65 |
| 2022-12-31 | 0.23 | -144.43 | -152.38 |
| 2022-09-30 | 0.42 | -145.49 | -196.25 |
| 2022-06-30 | 0.67 | -140.43 | -193.52 |
| 2022-03-31 | 0.50 | -158.79 | -205.37 |
| 2021-12-31 | 20.38 | -120.33 | -167.81 |
| 2021-09-30 | 20.15 | -157.03 | -165.53 |
| 2021-06-30 | 19.88 | -131.06 | -217.56 |
| 2021-03-31 | 19.88 | -83.41 | -185.46 |
| 2020-12-31 | -92.14 | -169.84 |
Laporan Laba Rugi: EPS
- earnings per share basic untuk Atai Life Sciences N.V. pada 2025 Jun 30 adalah -0.69.
- laba per saham yang terdilusi untuk Atai Life Sciences N.V. pada 2025 Jun 30 adalah -0.69.
| Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
| 2025-06-30 | -0.69 | -0.69 |
| 2025-03-31 | -0.91 | -0.91 |
| 2024-12-31 | -0.93 | |
| 2024-09-30 | -0.79 | -0.79 |
| 2024-06-30 | -0.36 | -0.36 |
| 2024-03-31 | -0.21 | -0.21 |
| 2023-12-31 | -0.25 | |
| 2023-09-30 | -0.43 | -0.43 |
| 2023-06-30 | -0.93 | -0.93 |
| 2023-03-31 | -0.95 | -0.95 |
| 2022-12-31 | -0.98 | |
| 2022-09-30 | -1.28 | -1.27 |
| 2022-06-30 | -1.27 | -1.27 |
| 2022-03-31 | -1.40 | -1.40 |
| 2021-12-31 | -1.21 | |
| 2021-09-30 | -1.32 | -1.32 |
| 2021-06-30 | -1.97 | -1.97 |
| 2021-03-31 | -1.85 | -1.84 |
| 2020-12-31 | -1.83 |
Arus Kas: Operasi, Investasi, Pendanaan
- Nilai cash from operating activities untuk Atai Life Sciences N.V. per 2025 Jun 30 adalah -75.57 MM.
- Nilai cash from investing activities untuk Atai Life Sciences N.V. per 2025 Jun 30 adalah 30.17 MM.
- Nilai kas dari aktivitas pendanaan untuk Atai Life Sciences N.V. per 2025 Jun 30 adalah 72.41 MM.
| Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
| 2025-06-30 | -75.57 | 30.17 | 72.41 |
| 2025-03-31 | -77.70 | 36.69 | 64.98 |
| 2024-12-31 | -82.44 | 59.17 | 5.37 |
| 2024-09-30 | -80.10 | 51.79 | -3.24 |
| 2024-06-30 | -79.19 | -19.54 | -8.13 |
| 2024-03-31 | -85.58 | -57.84 | -8.56 |
| 2023-12-31 | -84.12 | -53.30 | -8.36 |
| 2023-09-30 | -92.66 | 27.58 | -0.82 |
| 2023-06-30 | -102.28 | 140.12 | 18.96 |
| 2023-03-31 | -101.59 | 143.91 | 20.86 |
| 2022-12-31 | -104.47 | -86.85 | 20.79 |
| 2022-09-30 | -94.47 | -215.53 | 23.43 |
| 2022-06-30 | -94.54 | -282.20 | 7.53 |
| 2022-03-31 | -70.71 | -292.29 | 379.50 |
| 2021-12-31 | -63.25 | -81.28 | 409.86 |
| 2021-09-30 | -48.95 | -36.51 | 490.12 |
| 2021-06-30 | -26.29 | -41.27 | 504.30 |
| 2021-03-31 | -33.40 | -13.27 | 133.74 |
| 2020-12-31 | -20.77 | -28.27 | 113.05 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- p/e untuk Atai Life Sciences N.V. pada 2025 Jun 30 adalah -2.93.
- p/libro untuk Atai Life Sciences N.V. pada 2025 Jun 30 adalah 2.87.
- p/tbv untuk Atai Life Sciences N.V. pada 2025 Jun 30 adalah 2.94.
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
| Period End (TTM) | p/e | P/Book | P/TBV |
| 2025-06-30 | -2.93 | 2.87 | 2.94 |
| 2025-03-31 | 2.50 | 2.58 | |
| 2024-12-31 | 1.55 | 1.55 | |
| 2024-09-30 | -3.38 | 1.16 | 1.16 |
| 2024-06-30 | -6.54 | 0.99 | 0.99 |
| 2024-03-31 | -4.44 | 1.22 | 1.22 |
| 2023-12-31 | -3.48 | 0.87 | 0.87 |
| 2023-09-30 | -1.47 | 0.99 | 0.99 |
| 2023-06-30 | -1.83 | 1.13 | 1.13 |
| 2023-03-31 | -1.96 | 1.12 | |
| 2022-12-31 | 1.48 | 1.48 | |
| 2022-09-30 | 1.72 | 1.72 | |
| 2022-06-30 | -2.86 | 1.66 | 1.66 |
| 2022-03-31 | -4.86 | 2.11 | 2.11 |
| 2021-12-31 | -7.37 | 2.64 | 2.64 |
| 2021-09-30 | -10.54 | 4.73 | 4.73 |
| 2021-06-30 | |||
| 2021-03-31 | |||
| 2020-12-31 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
- EBIT/EV untuk Atai Life Sciences N.V. pada 2025 Jun 30 adalah -0.36.
- EBIT (3 tahun) / EV untuk Atai Life Sciences N.V. pada 2025 Jun 30 adalah -0.29.
| Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
| 2025-06-30 | -0.36 | -0.29 |
| 2025-03-31 | -0.50 | -0.37 |
| 2024-12-31 | -0.60 | -0.49 |
| 2024-09-30 | -0.32 | -0.57 |
| 2024-06-30 | -0.17 | -0.61 |
| 2024-03-31 | -0.24 | -0.48 |
| 2023-12-31 | -0.37 | -0.86 |
| 2023-09-30 | -1.55 | -2.06 |
| 2023-06-30 | -1.40 | -1.83 |
| 2023-03-31 | -1.18 | -1.46 |
| 2022-12-31 | -0.65 | -0.40 |
| 2022-09-30 | -0.43 | -0.26 |
| 2022-06-30 | -0.47 | -0.33 |
| 2022-03-31 | -0.38 | -0.28 |
| 2021-12-31 | -0.22 | -0.16 |
| 2021-09-30 | -0.12 | -0.04 |
| 2021-06-30 | ||
| 2021-03-31 | ||
| 2020-12-31 |
Efektivitas Manajemen
- roa untuk Atai Life Sciences N.V. pada 2025 Jun 30 adalah -0.69.
- roe untuk Atai Life Sciences N.V. pada 2025 Jun 30 adalah -0.88.
- roic untuk Atai Life Sciences N.V. pada 2025 Jun 30 adalah -0.82.
- croic untuk Atai Life Sciences N.V. pada 2025 Jun 30 adalah 0.13.
- ocroic untuk Atai Life Sciences N.V. pada 2025 Jun 30 adalah -0.43.
| Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
| 2025-06-30 | -0.69 | -0.88 | -0.82 | 0.13 | -0.43 |
| 2025-03-31 | -0.55 | -0.67 | -1.03 | -0.12 | -0.57 |
| 2024-12-31 | -0.44 | -0.53 | -0.76 | -0.19 | -0.47 |
| 2024-09-30 | -0.19 | -0.22 | -0.31 | -0.57 | -0.42 |
| 2024-06-30 | -0.12 | -0.14 | -0.14 | -0.62 | -0.35 |
| 2024-03-31 | -0.22 | -0.25 | -0.25 | -0.25 | -0.35 |
| 2023-12-31 | -0.20 | -0.23 | -0.23 | -0.23 | -0.32 |
| 2023-09-30 | -0.42 | -0.45 | -0.62 | 0.24 | -0.44 |
| 2023-06-30 | -0.43 | -0.46 | -0.62 | 0.25 | -0.44 |
| 2023-03-31 | -0.40 | -0.43 | -0.58 | 0.24 | -0.39 |
| 2022-12-31 | -0.41 | -0.42 | -0.63 | -0.92 | -0.30 |
| 2022-09-30 | -0.40 | -0.42 | -0.66 | -0.96 | -0.32 |
| 2022-06-30 | -0.41 | -0.42 | -0.60 | -1.15 | -0.29 |
| 2022-03-31 | -1.16 | -1.40 | -0.58 | 0.06 | -0.20 |
| 2021-12-31 | -1.48 | -1.74 | -0.43 | 0.68 | -0.11 |
| 2021-09-30 | -3.64 | -0.35 | 0.87 | -0.05 | |
| 2021-06-30 | -3.50 | -3.64 | -0.45 | 0.90 | -0.05 |
| 2021-03-31 | -2.99 | -3.10 | -1.48 | 0.70 | -0.27 |
| 2020-12-31 | -2.73 | -2.84 | -1.74 | 0.69 | -0.21 |
Gross Margins
- marjin kotor untuk Atai Life Sciences N.V. pada 2025 Jun 30 adalah -4.82.
- marjin bersih untuk Atai Life Sciences N.V. pada 2025 Jun 30 adalah -79.97.
- marjin operasi untuk Atai Life Sciences N.V. pada 2025 Jun 30 adalah -50.97.
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
| Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
| 2025-06-30 | -4.82 | -79.97 | -50.97 |
| 2025-03-31 | 1.00 | -484.64 | -333.41 |
| 2024-12-31 | 1.00 | -388.53 | -304.49 |
| 2024-09-30 | 1.00 | -153.63 | -277.80 |
| 2024-06-30 | 1.00 | -122.03 | -401.60 |
| 2024-03-31 | 1.00 | -128.10 | -399.59 |
| 2023-12-31 | 1.00 | -200.43 | -378.05 |
| 2023-09-30 | 1.00 | -533.37 | -506.86 |
| 2023-06-30 | 1.00 | -533.37 | -506.86 |
| 2023-03-31 | 1.00 | -550.56 | -534.08 |
| 2022-12-31 | 1.00 | -461.77 | -342.34 |
| 2022-09-30 | 1.00 | -461.77 | -342.34 |
| 2022-06-30 | 1.00 | -290.57 | -210.86 |
| 2022-03-31 | 1.00 | -414.04 | -320.14 |
| 2021-12-31 | -0.34 | -8.24 | -5.91 |
| 2021-09-30 | 0.61 | -8.22 | -7.79 |
| 2021-06-30 | 0.61 | -10.94 | -6.59 |
| 2021-03-31 | 0.83 | -9.33 | -4.20 |
| 2020-12-31 |
Pengenal dan Deskriptor
| Kunci Indeks Pusat (CIK) | 1840904 |
Grupong Pang-industriya
| SIC 2834 - Pharmaceutical Preparations |
